- Home
- PRCH vs CGEM Comparison
PRCH vs CGEM Comparison
Compare PRCH & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCH | CGEM |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.7M | 873.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRCH | CGEM |
|---|---|---|
| Price | $6.97 | $14.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $18.00 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.1M | 720.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $16.80 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $4.65 | $5.68 |
| 52 Week High | $19.44 | $16.74 |
Technical Indicators
Market Signals| Indicator | PRCH | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 53.32 |
| Support Level | $6.54 | $11.43 |
| Resistance Level | $8.29 | $16.74 |
| Average True Range (ATR) | 0.42 | 0.91 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 31.52 | 61.06 |
Price Performance
Historical ComparisonAbout PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.